Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key ...
The trial was able to elicit more than double the microdystrophin gene in patients after 90 days of treatment.
Shares of biotech company Solid Biosciences (NASDAQ: SLDB) skyrocketed on Feb. 18 after the firm released key clinical data.
Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...
The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, ...
Less than half of patients had undergone bone monitoring, suggesting a need for better clinical guidance and management of ...
There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
DMD Advocates advised Innov8 Workspaces India Limited on a secondary sale and primary investment by InCred Wealth and ...